Drug comparisons
Linagliptin vs Alogliptin
Linagliptin vs Alogliptin: comparing two DPP-4 inhibitors for type 2 diabetes including renal adjustment needs, cardiovascular risks, glycemic control and safety.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when selecting a DPP-4 inhibitor add-on therapy for type 2 diabetes, particularly in patients with varying degrees of renal function or cardiovascular disease.
Bottom line
Both are effective similar DPP-4 inhibitors; Linagliptin may be more convenient for patients with reduced kidney function.
All medication comparisons